Medicine that creates novel biochemical functions

Important results from the project

Inhibitors constitute current technology for "targeted medical therapy". This is today´s technology solution for treating diseases and is hugely successful and has built up the pharmaceutical industry, which has a turnover of trillions of SEK. Here, we want to generate a new technology solution, a class of small molecules that instead of inhibiting an enzyme have the potential to not only increase an existing enzymatic activity but also generate new biochemical reactions by acting as a co-catalyst. The aim here is to take this early project to proof-of-concept

Expected long term effects

In this project we have further characterized OGG1 activator molecule and done in vivo proof-of-concept in a liver disease model. We are further increasing the techniqual readiness level but have not yet reached the stage for pre-clinical development

Approach and implementation

** Denna text är maskinöversatt ** We have mainly carried out experimental investigations of the molecules we have identified or manufactured and in addition studied the effects in relevant disease models, which is an eligibility requirements to be able to assess the effectiveness. Overall, the experiments have gone well or even exceeded expectations.